ABBVie Acquires Apogee Therapeutics for $10.9 Billion

AbbVie (ABBV) announced it will acquire Apogee Therapeutics (APGE) for $10.9 billion, or $135.11 per share — a 49.5% premium to Apogee's June 19 closing price. AbbVie CEO Robert A. Michael called the deal an "excellent fit" and described Apogee's lead asset as having "mega-blockbuster potential," which AbbVie internally defines as peak annual sales exceeding $10 billion. The acquisition is expected to close in Q3 2026, pending Apogee shareholder approval and regulatory clearance.

Apogee's crown jewel is zumilokibart, an anti-IL-13 antibody in development for atopic dermatitis and asthma. Phase 2 data showed approximately two-thirds of patients achieved significant skin clearance at 16 weeks, with a dosing interval of once every three to six months — substantially less frequent than Sanofi and Regeneron's Dupixent (biweekly injections), which generated $14 billion in 2024 revenue and has set the commercial benchmark for IL-4/IL-13 pathway inhibition. If zumilokibart's longer dosing interval holds in Phase 3, it would represent a genuine differentiator that could capture a segment of the Dupixent market and expand into asthma and eosinophilic conditions.

The deal accelerates AbbVie's post-Humira immunology strategy. Humira biosimilar competition has compressed that franchise from a $20+ billion peak, and AbbVie's own Skyrizi and Rinvoq have performed well but have not yet filled the entire revenue gap. Apogee's pipeline also includes APG333 and APG273 targeting additional inflammatory indications. The $10.9 billion price tag adds to AbbVie's debt load, which was already elevated from the $63 billion Allergan acquisition in 2020 — a leverage concern offset by AbbVie's historically strong cash flow generation.